Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Long-Term Risks Of Seroquel XR Will Be Focus Of Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca commits to a post-market study but says broadened indications for generalized anxiety disorder and major depressive disorder would not broaden the risks.

You may also be interested in...



Seroquel XR Might Get Second Line For Depression, Anxiety Despite Safety Worry

A second-line indication for AstraZeneca's Seroquel XR (quetiapine) in major depressive disorder and generalized anxiety disorder remains possible following a unanimous FDA advisory committee vote that the drug is not "acceptably safe" for the monotherapy claims in MDD and GAD that AstraZeneca had been seeking

Seroquel XR Might Get Second Line For Depression, Anxiety Despite Safety Worry

A second-line indication for AstraZeneca's Seroquel XR (quetiapine) in major depressive disorder and generalized anxiety disorder remains possible following a unanimous FDA advisory committee vote that the drug is not "acceptably safe" for the monotherapy claims in MDD and GAD that AstraZeneca had been seeking

Seroquel XR Needs Long-Term Safety Data For Depression, Anxiety Monotherapy – FDA Panel

AstraZeneca does gets recommendation for the atypical antipsychotic as adjunct therapy in major depressive disorder.

Related Content

Topics

UsernamePublicRestriction

Register

PS069382

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel